Platino-resistance in Ovarian Cancer

  • End date
    May 25, 2029
  • participants needed
  • sponsor
    Institut Claudius Regaud
Updated on 1 August 2021
ovarian cancer


Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).

Patients will receive treatment (platinum based-chemotherapy) according to the standard practices.

A prospective database and an associated biological collection will be performed during 5

  • For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care.
  • Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study).

Study participation of each patient will be 5 years.

Condition Ovarian Epithelial Cancer, Epithelial Ovarian Cancer, Epithelial Ovarian Carcinoma, ovarian epithelial carcinoma, carcinoma of the ovary
Treatment Patients treated with platinum based-chemotherapy
Clinical Study IdentifierNCT03954171
SponsorInstitut Claudius Regaud
Last Modified on1 August 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years old
Epithelial ovarian cancer at initial diagnosis (all stages)
Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
Indication of platinum based-chemotherapy
Patient affiliated to the french social security system
Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure

Exclusion Criteria

Non-epithelial ovarian tumor, borderline ovarian tumor
Patient with recurrent disease
Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse
Oncopole (IUCT-O)
Pregnant or breastfeeding women
Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note